|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
SHORT BLACK CANDLE
Trading: SELL @ $1.41
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading position. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This Japanese candlestick indicator can provide guidance on the short term battle between sellers and buyers from the companies recent trading.
Mesoblast (ASX:MSB) has formed a Short Black candlestick. This means, MSB has limited price movement derived from weak selling pressure. Given the limited timeframe in which signal has formed, further confirmation is required through volume and additional technical indicators.
This candlestick implies a relatively weak selling pressure with a limited price movement.
Calculation: Short Black Candlestick:
1) The body of the candlestick is black and small;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|BFC Beston Global Food||0.11||5||372,431||0||BEARISH|
|UOS United Overseas Australia||0.76||3.4||34,821||0||BEARISH|
|RRL Regis Resources||5.16||2||3,902,408||0||BEARISH|
|RMS Ramelius Resources||0.76||1.3||3,996,500||-1||BEARISH|
|QMS Qms Media||0.82||1.2||324,866||0||BEARISH|
|EVN Evolution Mining||4.34||0.9||11,923,929||0||BEARISH|
|SLK Sealink Travel||3.7||0.8||13,691||0||BEARISH|
|CNI Centuria Capital||1.81||0.6||157,492||0||BEARISH|
|ENN Elanor Investors||1.82||0.3||424,474||0||BEARISH|